SOPHiA GENETICS Raises $30 Million in Series D Funding

SOPHiA GENETICS today announced the close of a $30-million Series D funding round. The round was led by London-based Balderton Capital, joined by 360º Capital Partners, alongside existing investors British tech star Mike Lynch’s Invoke Capital and Alychlo, Belgian pharmaceutical entrepreneur Marc Coucke’s investment firm.

The company’s technology, SOPHiA AI, accurately analyzes and detects all types of genomic variants to help clinicians better diagnose and treat their patients. Its innovative technology and global approach were recently recognized by the MIT Technology Review’s “50 Smartest Companies,” which ranked SOPHiA GENETICS thirtieth. SOPHiA is being used daily by 334 hospitals across 53 countries, and it has tested more than 125,000 patients to date.

The company will use the new funding to continue developing its technology. The company will also continue recruiting top talent and accelerate hospitals’ adoption of clinical genomics testing.